CEO Total Pay
$1.1M
FY2022 Summary Compensation, below median
FY2022 SEC EDGAR DEF 14A
Reata Pharmaceuticals Inc CEO pay ratio
The CEO earned $1.1M in FY2022 against median worker pay of $146,158 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2023-04-28
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2022
Data updated August 2026
Subscribe to Reata Pharmaceuticals Inc CEO pay filing updates (RSS)
CEO-to-worker pay ratio
8:1
Below Average (Scale: 0–1000:1)
CEO pay
$1.1M
Median worker
$146,158
Latest filing FY2022. This company's newest DEF 14A on file is for FY2022, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Reata Pharmaceuticals Inc reported a 8:1 CEO-to-worker pay ratio in FY2022 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 8:1
- FY2022 disclosed
- CEO total
- $1.1M
- Summary Compensation Table total
- Median worker
- $146,158
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2022
A component-level pay breakdown is not reported in Reata Pharmaceuticals Inc's structured SEC pay-ratio disclosure. See our methodology →
Filing-year trail · Reata Pharmaceuticals Inc
Complete DEF 14A pay-ratio filings for this CIK across FY2021–2022. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).
- Latest ratio
- 8:1
- FY2022
- vs prior FY
- -8:1
- from FY2021 16:1
- CEO $ YoY
- -73%
- $1.1M latest
- Filings shown
- 2
- FY2021–2022
| FY | CEO pay | Δ pay | Median worker | Pay ratio | Δ ratio |
|---|---|---|---|---|---|
| 2021 | $4.0M | - | $244,581 | 16:1 | - |
| 2022 | $1.1M | -73% | $146,158 | 8:1 | -8:1 |
Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1358762, FY2021–2022. Adjacent-year deltas only.
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
8:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$1.1M
Companies in Industry
168
vs. Industry Median
Below
Reata Pharmaceuticals Inc: near-parity Item 402(u) ratio
Reata Pharmaceuticals Inc stamps FLOOR · ELITE-MED at 8:1 against $146,158 median worker pay in FY2022. the CEO earned 8× the median employee ($146,158) in FY2022.
At $146,158 median worker pay, the FLOOR stamp is near pay-parity territory under LIGHT CEO total.
Pay Ratio
8:1
Below typical
What FY2022 shows for Reata Pharmaceuticals Inc
Reata Pharmaceuticals Inc stamps FLOOR · ELITE-MED at 8:1 against $146,158 median worker pay in FY2022. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Reata Pharmaceuticals Inc's $1.1M CEO total is at or below the $7.9M industry median CEO pay.
Reata Pharmaceuticals Inc stamps FLOOR · LIGHT · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2022
- Total Compensation
- $1.1M
- Median Employee Pay
- $146,158
- Pay Ratio
- 8:1
- Filing Date
- 2023-04-28
Company Info
- CIK
- 1358762
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2834
- State
- DE
SEC EDGAR DEF 14A for CIK 1358762, FY2022. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Reata Pharmaceuticals Inc stamps FLOOR · ELITE-MED at 8:1 against $146,158 median worker pay in FY2022.
Read with Reata Pharmaceuticals Inc
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps FLOOR · LIGHT · ELITE-MED.
American National Bankshares Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.1M (Δ $3K heavier vs Reata Pharmaceuticals Inc); FLOOR · PAR-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Ziprecruiter, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.1M (Δ $11K lighter vs Reata Pharmaceuticals Inc); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Peloton Interactive, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.1M (Δ $12K lighter vs Reata Pharmaceuticals Inc); FLOOR · ELITE-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Kinder Morgan, Inc. · LIGHT
ABS(ceo_total_comp) peer at $1.1M (Δ $12K heavier vs Reata Pharmaceuticals Inc); FLOOR · HIGH-MED vs this page's FLOOR · LIGHT · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Reata Pharmaceuticals Inc stamps FLOOR · LIGHT · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · FLOOR
See where FLOOR · LIGHT packages sit on the national leaderboard after reading Reata Pharmaceuticals Inc.
Ratio primer · FLOOR
Reata Pharmaceuticals Inc's FLOOR stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Reata Pharmaceuticals Inc (CIK 1358762), FY2022. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.